Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284992 | 0.89 | TRPV1 (0.41) | TRPV1KDM4ETSHR | |
| SCHEMBL1285378 | 0.89 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL14378404 | 0.88 | KDM4E (0.40) | TRPV1KDM4ETSHRNPSR1HSD17B10 | |
| SCHEMBL1284900 | 0.85 | HSD17B10 (0.46) | TRPV1KDM4ETSHRNPSR1HSD17B10 | |
| SCHEMBL1284963 | 0.84 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL1285086 | 0.84 | TRPV1 (0.39) | TRPV1PPARG | |
| SCHEMBL1284988 | 0.83 | LPAR2 (0.41) | TRPV1TSHR | |
| SCHEMBL4556599 | 0.79 | HSD17B10 (0.46) | KDM4ETSHRNPSR1HSD17B10 | |
| SCHEMBL4556598 | 0.79 | HSD17B10 (0.46) | KDM4ETSHRNPSR1HSD17B10 | |
| SCHEMBL1644149 | 0.79 | PPARG (0.36) | TRPV1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | claimed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885KDM4E 4075/4885TSHR 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.